ID

12959

Description

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression; ODM derived from: https://clinicaltrials.gov/show/NCT00033514

Lien

https://clinicaltrials.gov/show/NCT00033514

Mots-clés

  1. 07/01/2016 07/01/2016 -
Téléchargé le

7 janvier 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00033514

Eligibility Breast Cancer NCT00033514

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
women aged > 18 years
Description

age, gender

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0079399
histologically documents metastatic breast cancer
Description

histology metastasis

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019638
UMLS CUI [1,2]
C0027627
her2 positive using fish
Description

FISH her2 positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0162789
UMLS CUI [1,2]
C0242957
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
Description

previous treatment

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
Description

measureable disease

Type de données

boolean

Alias
UMLS CUI [1]
C0475440
UMLS CUI [2]
C0860888
ecog performance status of 0 to 2
Description

ecog performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
a life expectancy of > 3 months
Description

life expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
use of effective means of contraception
Description

contraception

Type de données

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
Description

chemotherapy, herceptin

Type de données

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0338204

Similar models

Eligibility Breast Cancer NCT00033514

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
age, gender
Item
women aged > 18 years
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
histology metastasis
Item
histologically documents metastatic breast cancer
boolean
C0019638 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
FISH her2 positive
Item
her2 positive using fish
boolean
C0162789 (UMLS CUI [1,1])
C0242957 (UMLS CUI [1,2])
previous treatment
Item
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
boolean
C0087111 (UMLS CUI [1])
measureable disease
Item
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
boolean
C0475440 (UMLS CUI [1])
C0860888 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
a life expectancy of > 3 months
boolean
C0023671 (UMLS CUI [1])
contraception
Item
use of effective means of contraception
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
chemotherapy, herceptin
Item
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
boolean
C0392920 (UMLS CUI [1])
C0338204 (UMLS CUI [2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial